ResMed Inc. (RMD)
NYSE: RMDHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
RMD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $33.14B
- P/E (TTM)
- 21.46
- Forward P/E
- 17.82
- EPS (TTM)
- $10.98
- Dividend yield
- 1.04% ($2.46)
- Ex-dividend date
- Nov 12, 2026
- 52-week range
- 180.27 – 277.67
- Day range
- 234.70 – 242.43
- Volume / Avg
- 1.37M / 1.30M
- Beta
- —
- Shares outstanding
- 140.66M
52-week range
RMD stock today
On Nov 20, RMD ended the session at $235.63, shedding $1.25 (0.53%), versus the S&P 500's 3.70% decline. Shares are 15.1% below their 52-week high of $277.67, set on Feb 10, 2026 and 30.7% above the 52-week low of $180.27, in the middle of the past year's range. RMD is down 2.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.0%.
At 21.5x trailing earnings, ResMed trades below the peer-group median of 62.1x. Its forward P/E of 17.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. ResMed pays an annual dividend of $2.46 per share, a 1.04% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About ResMed
Company profileResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Michael J. Farrell BE, MBA, SM
- Headquarters
- San Diego, CA
- Employees
- 11,370
- Website
- resmed.com
Financial highlights
Full financialsIn fiscal 2026, ResMed generated $5.65 billion in revenue, up 9.9% from fiscal 2025, its 17th consecutive year of revenue growth. Net income was $1.52 billion (+8.8% year over year), for a net margin of 26.9% versus a median of 21.8% in the prior 5 years. Gross margin was 61.1% (up from 59.4%) and operating margin 33.4%.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B |
| Growth | +9.85% | +9.84% | +10.95% | +18.02% | +11.93% |
| Net income | $1.52B | $1.40B | $1.02B | $897.56M | $779.44M |
| EPS (diluted) | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 |
Analyst forecast
ForecastConsensus (20 analysts)
buy
Avg. price target
$264.33+12.18%
- Strong buy 2
- Buy 7
- Hold 10
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $2.55 vs $2.67
- Surprise
- -4.49%
Dividends
Dividend history- Annual dividend
- $2.46
- Dividend yield
- 1.04%
- Last payment
- $0.66
- Ex-dividend date
- Nov 12, 2026
RMD news
All RMD news- Is This the Right Time to Hold Resmed Stock in Your Portfolio?NasdaqRMD, IDXX, PODD, BLCO
- ResMed Inc. Reduces Board Size to ten (10) and Approves Fiscal Year 2027 PSU Award DesignNasdaq
- Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?NasdaqABT, ISRG, RMD
- INSP Is Up 12.1% in Three Months: Can Its Rally Continue From Here?NasdaqINSP, RMD, NYXH
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of ResMed Inc. (NYSE: RMD).PR Newswire
- Zoetis Takes Over #296 Spot From ResMedNasdaqZTS, RMD
- ResMed Now #295 Largest Company, Surpassing Mettler-Toledo InternationalNasdaqRMD, MTD
- ResMed: A Quality Compounder, But Not Yet A BargainSeeking Alpha
ResMed peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DXCMDexCom Inc. | 79.32 | -1.08% | $29.58B | vs RMD |
| WSTWest Pharmaceutical Services Inc. | 390.30 | -1.61% | $27.19B | vs RMD |
| MDLNMedline Inc. Class A | 37.04 | -2.11% | $48.75B | vs RMD |
| SOLVSolventum Corporation | 84.50 | -1.52% | $14.36B | vs RMD |
| GKOSGlaukos Corporation | 237.31 | -0.33% | $14.05B | vs RMD |
| BAXBaxter International Inc. | 25.39 | 0.00% | $13.14B | vs RMD |
| PENPenumbra Inc. | 319.12 | -0.28% | $12.58B | vs RMD |
| PODDInsulet Corporation | 133.17 | -2.96% | $9.24B | vs RMD |
Indexes, lists and sector
ResMed stock FAQ
What is ResMed's stock price today?
RMD last traded at $235.63 as of Nov 20, 4:00 PM EST, down 0.53% on the day. Prices are delayed at least 15 minutes.
Does ResMed pay a dividend?
Yes. ResMed pays $2.46 per share annually, a 1.04% yield. The most recent dividend of $0.66 had an ex-dividend date of Nov 12, 2026.
What is RMD's P/E ratio?
RMD trades at a trailing P/E ratio of 21.46 and a forward P/E of 17.82, compared with a median of 62.1 for its closest peers.
Is ResMed in the S&P 500?
Yes. ResMed (RMD) is a constituent of the S&P 500 index.
Who is ResMed's CEO?
Mr. Michael J. Farrell BE, MBA, SM is the chief executive officer of ResMed Inc., which has about 11,370 employees.
Has RMD ever split its stock?
Yes. The most recent RMD stock split was a 2-for-1 split on Aug 31, 2010, one of 4 splits on record.
What is the RMD 52-week high?
The 52-week high for RMD is $277.67 and the 52-week low is $180.27. The stock is currently 15.1% below its high.